

09/787835

**FIRST CLASS MAIL CERTIFICATE**

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner of Patents and Trademarks, United States Patent and Trademark Office, Washington, D.C. 20231.

Linda O. Palladino

October 2, 2001

Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application Of : Stahl, N. and Yancopoulos, G.D.  
USSN : 09/787,835  
Filed : March 22, 2001  
For : RECEPTOR BASED ANTAGONISTS,  
AND METHODS OF MAKING AND  
USING  
Examiner : Not Yet Known  
Group : Not Yet Known

October 2, 2001

Commissioner for Patents  
U.S. Patent and Trademark Office  
Washington, D.C. 20231

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97(c) AND 1.98**

S I R :


Submitted herewith is PTO Form 1449 to make of record those references of which Applicants are aware which may be pertinent to an examination of the captioned patent application on the merits. Copies of the listed references are enclosed. In addition, a copy of Irish Patent Number IE 912256, the English translation of German Patent Number EP 0 835 939 A2, is attached herewith.

No fee is deemed necessary in connection with filing this Information Disclosure Statement. However, if any additional fee is necessary, authorization is hereby given to charge the amount of any such additional fee to Deposit Account No. 18-0650.

Respectfully submitted,

---

Gail M. Kempler  
Reg. No. 32,143  
Joseph M. Sorrentino  
Reg. No. 32,598  
Attorneys for Applicants  
Linda O. Palladino  
Reg. No. 45,636  
Patent Agent for Applicants  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400



FORM PTO-1449

Att. Docket No. REG 203B-US

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 203B-US  
Serial No. : 09/787,835  
Applicant(s): : Stahl, N. and Yancopoulos, G.D.  
Date Filed : March 22, 2001  
For : RECEPTOR BASED ANTAGONISTS,  
AND METHODS OF MAKING AND  
USING  
Examiner : Not Yet Known  
Group Art Unit : Not Yet Known


October 2, 2001

## U.S. PATENT DOCUMENTS

Examiner Initials	Patent/ Publication Number	Patent/ Publication Date	Serial Number	Filing Date	Name
_____	<u>5,470,952</u>	<u>11/28/95</u>	_____	_____	<u>Stahl, N., et al.</u>
_____	_____	_____	<u>60/101,858</u>	<u>9/25/98</u>	<u>Stahl, N. &amp; Yancopoulos, G.D.</u>
_____	_____	_____	<u>09/313,942</u>	<u>5/19/99</u>	<u>Stahl, N. &amp; Yancopoulos, G.D.</u>

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
_____	<u>EP0835939A2</u>	<u>6/22/91</u>	<u>EP</u>	_____	<u>X</u>	_____
_____	<u>EP0533006A1</u>	<u>9/5/92</u>	<u>EP</u>	_____	_____	_____
_____	<u>EP0864585A1</u>	<u>9/16/98</u>	<u>EP</u>	_____	_____	_____
_____	<u>WO93/10151</u>	<u>5/27/93</u>	<u>PCT</u>	_____	_____	_____
_____	<u>WO93/18047</u>	<u>9/16/93</u>	<u>PCT</u>	_____	_____	_____
_____	<u>WO93/19163</u>	<u>9/30/93</u>	<u>PCT</u>	_____	_____	_____
_____	<u>WO93/19777</u>	<u>10/14/93</u>	<u>PCT</u>	_____	_____	_____



✓	WO94/22914	10/13/94	PCT			
✓	WO95/06737	3/9/95	PCT			
✓	WO95/10611	4/20/95	PCT			
✓	WO96/11213	4/18/96	PCT			
✓	WO96/23881	8/8/96	PCT			
✓	WO96/04389	2/15/96	PCT			
✓	WO96/35783	11/14/96	PCT			
✓	WO97/15669	5/1/97	PCT			
✓	WO97/23613	7/3/97	PCT			
✓	WO97/31946	9/4/97	PCT			
✓	WO98/02558	1/22/98	PCT			
✓	WO99/37772	7/29/99	PCT			

#### OTHER DOCUMENTS

Examiner  
 Initials

- CELL, 1991, Aruffo, A., et al., "CD62/P-Selectin Recognition of Myeloid and Tumor Cell Sulfatides", 67:35-44. ✓
- CANCER RES, 1993, Bargetzi, M.J., et al., "Interleukin-1 $\beta$  Induces Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein in Humans," 53:4010-4013. ✓
- J. of BIO. CHEM., 1994, Bassing, C., et al., "A Single Heteromeric Receptor Complex Is Sufficient to Mediate Biological Effects of Transforming Growth Factor- $\beta$  Ligands", 269(21):14861-14864. ✓
- J. of BIO. CHEM., 1990, Baumann, M., et al., "Molecular Cloning, Characterization and Functional Expression of the Rat Liver Interleukin 6 Receptor", 265(32):19853-19862. ✓
- NEURON, 1991, Bazan, J.F., "Neurotrophic Cytokines in the Hematopoietic Fold", 7:197-208. ✓
- PROC. NATL. ACAD. SCI., 1990, Bazan, J.F., "Structural design and molecular evolution of a cytokine receptor superfamily" 87:6934-6938. ✓
- J. of VIR, 1992, Cheung, S.C., et. al., "A Recombinant Fab Expressed in *Escherichia coli* Neutralizes Rabies Virus", 66(11):6714-6720. ✓



SCIENCE, 1991, Davis, S., et. al., "The Receptor for Ciliary Neurotrophic Factor", 253:59-63. ✓

SCIENCE, 1993, Davis, S., et. al., "Released Form of CNTF Receptor  $\alpha$  Component as a Soluble Mediator of CNTF Responses", 259:1736-1739. ✓

SCIENCE, 1993, Davis, S., et. al., "LIFR $\beta$  and gp130 as Heterodimerizing Signal Transducers of the Tripartite CNTF Receptor", 260:1805-1808. ✓

BIOCHIMICA et BIOPHYSICA ACTA, 1997, Derynck, R. and Feng, X., "TGF- $\beta$  receptor signaling", F105-150. ✓

EUR. CYTOKINE NETW, 1996, Duschl, A. and Sebald, W., "Transmembrane and intracellular signalling by interleukin-4: receptor dimerization and beyond," 7:37-49. ✓

THE EMBO JOURNAL, 1991, Gearing, D.P., et. al., "Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130", 10(10):2839-2848. ✓

SCIENCE, 1992, Gearing, D.P., et. al., "The IL-6 Signal Transducer, gp130: An Oncostatin M Receptor and Affinity Converter for the LIF Receptor", 255:1434-1437. ✓

J. of BIOL. CHEM., 1995, Greenfeeder, S.A., et. al., "Molecular Cloning and Characterization of a Second Subunit of the Interleukin 1 Receptor Complex", 270(23):13757-13765. ✓

CELL, 1990, Hibi, M., et. al., "Molecular Cloning and Expression of an IL-6 Signal Transducer, gp130", 63:1149-1157. ✓

THE EMBO JOUR, 1994, Hilton, D.J., et. al., "Cloning of a murine IL-11 receptor  $\alpha$ -chain; requirement for gp130 for high affinity binding and signal transduction", 13(20):4765-4775. ✓

CELL, 1992, Ip, N.Y., et. al., "CNTF and LIF Act on Neuronal Cells via Shared Signaling Pathways That Involve the IL-6 Signal Transducing Receptor Component gp130", 69:1121-1132. ✓

IMMUNOBIOLOGY-THE IMMUNE SYSTEM IN HEALTH AND DISEASE, 2nd Edition, Janeway-Travers, Appendix II "Cytokines and their receptors", A:9. ✓


J. of CLIN. IMMUNOL., 1996, Kennedy, M.K., and Park, L.S., "Characterization of Interleukin-15 (IL-15) and the IL-15 Receptor Complex", 16(3): 134-143. ✓

GENES AND DEVELOPMENT, 1994, Kingsley, D.M., "The TGF- $\beta$  superfamily: new members, new receptors, and new genetic tests of function in different organisms", 8:133-146. ✓

SCIENCE, 1992, Kishimoto, T., et. al., "Interleukin-6 and Its Receptor: A Paradigm for Cytokines", 258:593-597. ✓



- SCIENCE, 1993, Kondo, M., et. al., "Sharing of the Interleukin-2 (IL-2) Receptor  $\gamma$  Chain Between for IL-2 and IL-4", 262:1874-1877. ✓
- THE EMBO JOURNAL, 1997, Kotenko, S.V., et. al., "Identification and functional characterization of a second chain of the interleukin-10 receptor complex", 16(9):5894-5903. ✓
- J. of BIOL. CHEM., 1995, Kotenko, S.V., et. al., "Interaction between the Components of the Interferon  $\gamma$  Receptor Complex", 10(36):20915-20921. ✓
- PROC. NATL. ACAD. SCI., 1992, Layton, M.J. et al., "A major binding protein for leukemia inhibitory factor in normal mouse serum: Identification as a soluble form of the cellular receptor", 89:8616-8620. ✓
- MOL. and CELL. BIOL., 1997, Lebrun, J.J., and Vale, W.W., "Activin and Inhibin I Have Antagonistic Effects on Ligand-Dependent Heteromerization of the Type I and Type II Activin Receptors and Human Erythroid Differentiation", 17(3):1682-1691. ✓
- J. of IMMUNOL., 1993, Lewis, A.P., et al., "Rescue, Expression, and Analysis of a Neutralizing Human Anti-Hepatitis A Virus Monoclonal Antibody", 151(5):2829-2838. ✓
- ANNUAL REVIEW OF IMMUNOLOGY, 1992, Miyajima, A., et. al., "Cytokine Receptors and Signal Transduction", 10:295-331. ✓
- J. of IMMUNOL., 1993, Mohler, K.M., et. al., "Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists", 151(3):1548-1561. ✓
- PROC. NATL. ACAD. SCI., 1991, Murakami, M., et. al., "Critical cytoplasmic region of the interleukin 6 transducer gp130 is conserved in the cytokine receptor family", 88:11349-11353. ✓
- SCIENCE, 1993, Murakami, M., et. al., "IL-6-Induced Homodimerization of gp130 and Associated Activation of a Tyrosine Kinase", 260:1808-1810. ✓
- BLOOD, 1993, Narazaki, M., et. al., "Soluble Forms of the Interleukin-6 Signal Transducing Receptor Component gp130 in Human Serum Possessing a Potential to Inhibit Signals Through Membrane-Anchored gp130", 82(4):1120-1126. ✓
- PROC. NATL. ACAD. SCI., 1991, Rose, T.M., and Bruce, G., "Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6", 88:8641-8645. ✓



CUR OPIN CELL BIO, 1994, Sato, N., and Miyajima, A.,  
"Multimeric cytokine receptors: common versus specific functions",  
66:174-179. ✓

BIOCHEM and BIOPHYS RES COMM, 1997, Seipelt, I., et al.,  
"Overexpression, Purification, and Use of a Soluble Human  
Interleukin-4 Receptor  $\alpha$ -chain/Ig $\gamma$ 1 Fusion Protein for Ligand Binding  
Studies," 239:534-542. ✓

J. of BIOL. CHEM., 1993, Stahl, N., et. al., "Cross-linking Identifies  
Leukemia Inhibitory Factor-binding Protein as a Ciliary Neurotrophic  
Factor Receptor Component", 268(11):7628-7631. ✓

SCIENCE, 1994, Stahl, N., et. al., "Association and Activation  
of Jak-Tyk Kinases by CNTF-LIF-OSM-IL-6  $\beta$  Receptor  
Components", 263:92-95. ✓

SCIENCE, 1995, Stahl, N., et. al., "Choice of STATs and Other  
Substrates Specified by Modular Tyrosine-Based Motifs in  
Cytokine Receptors", 267:1349-1353. ✓

CELL, 1993, Stahl, N., and Yancopoulos, G.D., "The Alphas, Betas,  
and Kinases of Cytokine Receptor Complexes", 74:587-590. ✓

J. of NEUROBIOL., 1994, Stahl, N., and Yancopoulos, G.D., "The  
Tripartite CNTF Receptor Complex: Activation and Signaling Involves  
Components Shared with Other Cytokines", 25(11):1454-1466. ✓

FASEB JOURNAL, 1999, Stahl, N., et al., "Cytokine Traps:  
Heteromeric Receptor-Based Protein Therapeutics that Function as  
High-Affinity Blockers of Cytokine Action," Abstract, 1457. ✓

CELL, 1989, Taga, T., et. al., "Interleukin-6 Triggers the  
Association of its Receptor with a Possible Signal Transducer,  
gp130", 58:573-581. ✓

CELL, 1982, Takahashi, N., et. al., "Structure of Human  
Immunoglobulin Gamma Genes: Implications for Evolution  
of a Gene Family", 29:671-679. ✓

J. of BIOL. CHEM., 1994, Ward, L.D., et. al., "High Affinity  
Interleukin-6 Receptor Is a Hexameric Complex Consisting of  
Two Molecules Each of Interleukin-6, Interleukin-6 Receptor,  
and gp130", 269(37):23286-23289. ✓

J. of BIOL. CHEM., 1997, Wesche, H., et. al., "The Interleukin-1  
Receptor Accessory Protein (IL-1RAcP) Is Essential for IL-1 induced  
Activation of Interleukin -1 Receptor-associated Kinase (IRAK) and  
Stress-activated Protein Kinases (SAP Kinases)", 272(12):7727-7731. ✓

MINERAL AND ELECTROLYTE METABOLISM, 1998, Wrana, J.,  
"TGF- $\beta$  Receptors and Signaling Mechanisms", 24:120-130. ✓



SCIENCE, 1988, Yamasaki, K., et. al., "Cloning and Expression of the Human Interleukin-6 (BSF-2/IFN $\beta$ ) Receptor", 241:825-828.

EXAMINER  
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Gail Kempler  
Reg. No. 32,143  
Joseph M. Sorrentino  
Reg. No. 32,598  
Attorneys for Applicant  
Linda O. Palladino  
Reg. No. 45,636  
Patent Agent for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400